Latanoprost /(CAS 130209-82-4)/ API

Latanoprost (CAS 130209-82-4) is a high-purity pharmaceutical API, a synthetic prostaglandin F₂α analogue and selective FP receptor agonist. Its lipid-soluble molecular structure enables rapid ocular penetration, binding to FP receptors in the ciliary muscle to relax connective tissues, thereby enhancing aqueous humor outflow via the uveoscleral pathway. Unlike conventional glaucoma medications, it does not reduce aqueous humor production or affect systemic blood pressure, offering targeted IOP reduction with minimal systemic side effects.

As a pale yellow liquid with excellent compatibility for ophthalmic formulations, it is ideal for eye drops—the primary clinical dosage form. It meets the core needs of ophthalmic drug manufacturers, glaucoma therapy developers, and clinical supply chains. Widely used to lower elevated intraocular pressure in open-angle glaucoma and ocular hypertension patients, it provides sustained 24-hour efficacy with once-daily administration. Produced under strict GMP standards, each batch undergoes rigorous purity and stability testing to meet international pharmacopoeia requirements, ensuring reliable clinical performance for vision protection.